

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CCIDConsulting

賽迪顧問股份有限公司

CCID CONSULTING COMPANY LIMITED*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 02176)

www.ccidconsulting.com

SUPPLEMENTAL ANNOUNCEMENT

CONNECTED TRANSACTION

**ENTERING INTO FUND PARTNERSHIP AGREEMENT IN RELATION
TO ESTABLISHMENT OF INVESTMENT FUND**

Reference is made to the announcement of CCID Consulting Company Limited* (the “**Company**”) dated 25 November 2020 (the “**First Announcement**”) and 22 December 2020 (the “**Second Announcement**”) with respect to the entering into fund partnership agreement in relation to establishment of investment fund (“**Fund Partnership Agreement**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the First Announcement.

The Board would like to provide an amendment to the principal terms of the Fund Partnership Agreement as below:

The Company (as Limited Partner) has signed the supplemental agreement with the Exchange Center (as Limited Partner), Xiachuan Capital (as Limited Partner) and CCID Tiandi (as General Partner) for the amendment to the principal terms in respect of the management fee of the Fund. As disclosed in the paragraph “OTHER SIGNIFICANT ARRANGEMENT IN RESPECT OF THE FUND” of the First Announcement, the management fee of the Fund will be paid by all partners to the Fund manager. Upon the amendment, the Fund manager will no longer collect any management fee but remains entitled to the performance-based compensation according to a specific percentage of the gains from the Fund investments.

In addition, the Board would like to supplement the following information of the Fund Partnership Agreement:

As disclosed in the paragraph “Details of the Investment of the Fund and a Description of and the Nature of the Underlying Investments” of the Second Announcement, the initial capital contribution of the Fund is RMB6 million. It is scheduled to use the said amount for equity investment (the “**Investment**”) by way of preference shares in a company (the “**Investee Company**”) established in Beijing, PRC specialized in genetic testing and health big data (基因測試健康大數據). The definitive investment agreement has been entered into by CCID Tiandi and the Investee Company on 1 March 2021 and the relevant terms and conditions have been finalized.

By Order of the Board
CCID Consulting Company Limited*
Ms. Xia Lin
Chairman

Beijing, the PRC, 18 August 2021

As at the date of this announcement, the Board comprises two executive Directors namely Ms. Xia Lin and Mr. Qin Hailin and four independent non-executive Directors namely Mr. Guo Xinpeng, Ms. Li Xuemei, Mr. Chen Yung-cheng and Mr. Hu Bin.

* *For identification purpose only*